StockNoteStockNote
Vietnam Pharmaceutical Corporation (DVN), formerly known as the Pharmaceutical Corporation, was established on April 1, 1971 on the basis of merging 03 departments under the Ministry of Health, namely the Drug Distribution Department, the Department of Medicinal Materials, and the Department of Production. VINAPHARM specializes in trading pharmaceuticals, functional foods, medical equipment, research and development of pharmaceutical science and technology. Vietnam Pharmaceutical Corporation officially operated in the form of a joint stock company from December 2016. VINAPHARM is currently one of the 3 units authorized by the Ministry of Health to conduct bioequivalence research with a bioequivalence research capacity of about 20 studies/year. In addition, the Corporation is the focal point to perform the tasks of the Ministry of Health to supply drugs in cases of natural disasters and epidemics emergencies. DVN has been traded on the UPCOM market since May 2017.
DVN currently has a market capitalization of roughly VND 4.011 billion, placing it in the mid-cap group on the Vietnamese stock market. Its current P/E of 5,8x is 71% below its own 8-year average (20,4x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 1,1x, 30% below its multi-year average of 1,5x. Return on equity (ROE) is at 17,8%, down from 20,3% the year before. Its debt-to-equity ratio of 0,4x is low, reflecting a conservative capital structure. In 2025, revenue grew 2% year-on-year while after-tax profit grew 69%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.